Nasdaq lpcn.

Lipocine Stock Up 3.8 %. Shares of NASDAQ LPCN opened at $2.73 on Tuesday. The firm has a market cap of $14.52 million, a PE ratio of -0.87 and a beta of …Nov 9, 2022 · Third quarter Ended September 30, 2022 Financial Results. Lipocine reported a net loss of $2.4 million, or ( $0.03 ) per diluted share for the quarter ended September 30, 2022, compared with a net ... Lipocine Inc. (NASDAQ: LPCN) Lipcocine Inc. is a clinical-stage biopharmaceutical company with a focus on the treatment of both endocrine and metabolic disorders. It utilizes its proprietary drug delivery technology to produce a large pipeline of compounds. This includes TLANDO, LPCN-1144, TLANDO XR, LPCN-1148, and LPCN …29 Mar, 2022, 07:05 ET. Commercial launch expected in 2Q 2022. SALT LAKE CITY, March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on ...

Virios Therapeutics (NASDAQ:VIRI) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and …SALT LAKE CITY, Nov. 1, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a specialty pharmaceutical company, today announced the completion of enrollment in the ambulatory blood pressure ("ABPM ...28 Sep, 2021, 08:00 ET. SALT LAKE CITY, Sept. 28, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...

SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ...Mar 10, 2023 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors declared a dividend of one one ...

Lipocine Inc. (NASDAQ: LPCN) Lipcocine Inc. is a clinical-stage biopharmaceutical company with a focus on the treatment of both endocrine and metabolic disorders. It utilizes its proprietary drug delivery technology to produce a large pipeline of compounds. This includes TLANDO, LPCN-1144, TLANDO XR, LPCN-1148, and LPCN …Lipocine Inc. Common Stock (LPCN) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. ... Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.SALT LAKE CITY - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, announced that Antares Pharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration ('FDA') has accepted its New …

Lipocine Inc (NASDAQ:LPCN). 2.56. Delayed Data. As of Dec 01. +0.15 / +6.22%. Today's Change. 2.31. Today|||52-Week Range. 10.33. -62.14%. Year-to-Date. Quote

Mar 31, 2023 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 1Q:23 Financial and Operational Results Efforts year to date for Lipocine Inc. (NASDAQ:LPCN) were dominated by the ...

SALT LAKE CITY, Feb. 11, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in its infringement lawsuit against Clarus Therapeutics, Inc. ("Clarus") in the United States District Court ("Delaware") related to …Nov 8, 2023 · Quarter Ended September 30, 2023 Financial Results. Lipocine reported a net loss of $6.7 million, or ($1.27) per diluted share, for the three months ended September 30, 2023, compared with a net ... Nov 13, 2023 · SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ... SALT LAKE CITY, Sept. 17, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr ...May 11, 2023 · SALT LAKE CITY, May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary ... Nov 10, 2021 · SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial ...

SALT LAKE CITY, March 3, 2021 - /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the ENDO 2021 Conference, to take place March 20-23, 2021.TLANDO is an oral …SALT LAKE CITY, May 26, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United ...Mar 31, 2023 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 1Q:23 Financial and Operational Results Efforts year to date for Lipocine Inc. (NASDAQ:LPCN) were dominated by the ... (NASDAQ: LPCN) forecast ROA is 32.86%, which is higher than the forecast US Biotechnology industry average of 11.78%. What is LPCN's Price Target? According to 1 Wall Street analyst that have issued a 1 year LPCN price target, the average LPCN price target is $33.00 , with the highest LPCN stock price forecast at $33.00 and the lowest …SALT LAKE CITY, Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will ...Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are ...43053e0.BvyjoXDK4vyzPj9jPCzC6nYZaj5-AJZQTaA_XM6iJCk.Pqj27Qe6rZn4cg8Iak23njphW0oPNqA7HNJoEomXEBw1kOnSKYyXndVGCw …

SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended ...Oct 26, 2023 · Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (“LPCN 1111”), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone ...

Nov 13, 2023 · Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are ... Jun 30, 2023 · 1,936,693. 327,183. 5.919296. Back to LPCN Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ... ○ Executive catalyst in taking Lipocine (NASDAQ: LPCN) public via a reverse merger raising $52M in a PIPE and a fully underwritten follow-on offering and ...SALT LAKE CITY, June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States ...Nov 9, 2022 · Third quarter Ended September 30, 2022 Financial Results. Lipocine reported a net loss of $2.4 million, or ( $0.03 ) per diluted share for the quarter ended September 30, 2022, compared with a net ... Nov 14, 2023 · Lipocine has generated ($3.14) earnings per share over the last year ( ($3.14) diluted earnings per share). Earnings for Lipocine are expected to grow in the coming year, from ($2.19) to ($1.47) per share. Lipocine has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 8th, 2024 ... SALT LAKE CITY, April 17, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN ), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the ...SALT LAKE CITY, May 7, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results ...

Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company that is involved in the research and development of pharmaceutical products for the treatment of neuroendocrine and ...

The new research reports from Market Source Research, available for free download at the links above, examine Arcimoto, Inc. (NASDAQ:FUV), ADOMANI, Inc. (NASDAQ:ADOM), Lipocine Inc. (NASDAQ:LPCN ...

Virios Therapeutics (NASDAQ:VIRI) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and …SALT LAKE CITY, Aug. 25, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its Phase 2 proof of concept LiFT ("Liver Fat intervention with oral Testosterone") clinical study, NCT04134091, investigating LPCN 1144 in men with biopsy-confirmed NASH.Jul 27, 2023 · LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis. ... Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ... ... Post-IPO Equity; Legal Name Lipocine Inc. Stock Symbol NASDAQ:LPCN; Company Type For Profit. Contact Email [email protected]; Phone Number 8019947383.... LPCN 1148 in the ongoing open label extension also showed improvement in sarcopenia SALT LAKE CITY, Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN) ...May 20, 2022 · By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT NASH Open Label Extension Study Results On May 12, 2022 Lipocine (NASDAQ:LPCN) announced results from its NASH Open Label Extension (OLE) study. Safety was confirmed with no observed safety signals over the 72-week duration of exposure and liver injury markers were either maintained or reduced with the use of LPCN 1144. The Get the latest Lipocine Inc (LPCN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …Lipocine Stock Up 3.8 %. Shares of NASDAQ LPCN opened at $2.73 on Tuesday. The firm has a market cap of $14.52 million, a PE ratio of -0.87 and a beta of …Complete Lipocine Inc. stock information by Barron's. View real-time LPCN stock price and news, along with industry-best analysis.

Nov 8, 2023 · Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products ... Nov 8, 2023 · Quarter Ended September 30, 2023 Financial Results. Lipocine reported a net loss of $6.7 million, or ($1.27) per diluted share, for the three months ended September 30, 2023, compared with a net ... By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 8, 2022 Lipocine (NASDAQ:LPCN) filed its second quarter 2022 Form 10-Q and posted its earnings release for the quarter ending June 30, 2022. Highlights for the second quarter 2022 and to-date include: New board of director appointments – April 2022 LPCN 1144Instagram:https://instagram. merrit medicalwhat time will arm start tradingvym tickerfh market SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical ... highest paying dividend stocks 2022exc dividend SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has ...SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2015, as well as ... beacon pointe 0.31%. $40.52B. LPCN | Complete Lipocine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Lipocine Inc share price live 2.7700, this page displays NASDAQ LPCN stock exchange data. View the LPCN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lipocine Inc real time stock price chart below. You can find more details ...SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) for the management of liver cirrhosis. The Phase 2 study is a ...